Key Insights

Highlights

Success Rate

82% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

6.5%

2 terminated out of 31 trials

Success Rate

81.8%

-4.7% vs benchmark

Late-Stage Pipeline

6%

2 trials in Phase 3/4

Results Transparency

67%

6 of 9 completed with results

Key Signals

6 with results82% success

Data Visualizations

Phase Distribution

31Total
Not Applicable (13)
Early P 1 (1)
P 1 (6)
P 2 (9)
P 4 (2)

Trial Status

Completed9
Recruiting7
Active Not Recruiting6
Unknown4
Withdrawn3
Terminated2

Trial Success Rate

81.8%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (31)

Showing 20 of 20 trials
NCT04789486Phase 1Recruiting

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

NCT02495896Phase 1Active Not Recruiting

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

NCT03138720Phase 2Completed

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

NCT05601323Not ApplicableActive Not RecruitingPrimary

A Study of Suizenji in Patients With Unresectable Pancreatic Cancer

NCT04395469Not ApplicableActive Not Recruiting

FAZA PET/MRI Pancreas

NCT05657743Not ApplicableRecruiting

A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advanced Pancreatic Cancer

NCT06026943Not ApplicableRecruiting

Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer

NCT04002479Not ApplicableActive Not Recruiting

Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer

NCT01972919Phase 2Active Not RecruitingPrimary

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

NCT07198659Early Phase 1RecruitingPrimary

A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer

NCT06135896Phase 2RecruitingPrimary

Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

NCT06592664Phase 1Withdrawn

Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC

NCT06099119Phase 4RecruitingPrimary

Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.

NCT03250273Phase 2Completed

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

NCT06278454Phase 1RecruitingPrimary

Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)

NCT04698915Phase 2Terminated

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

NCT02041936Not ApplicableActive Not RecruitingPrimary

Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System

NCT05251038Phase 1Withdrawn

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

NCT03602885Not ApplicableCompleted

EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options

NCT02282722Not ApplicableCompleted

Improving Informed Consent for Palliative Chemotherapy

Scroll to load more

Research Network

Activity Timeline